tyvaso
(treprostinil)United Therapeutics Corporation
Usage: Tyvaso is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability in patients, especially those with NYHA Functional Class III symptoms. It is also approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD), enhancing exercise capacity in affected patients.